The Effectiveness and Safety of Fenofibrate and Saroglitazar in the Treatment of Diabetic Dyslipidemia
Objective: This study aimed to evaluate the efficacy and safety of saroglitazar and fenofibrate in treating diabetic dyslipidemia. Study Design: Comparative cross-sectional study. Place and Duration of Study: The study was conducted at the Department of Biochemistry, Nishtar Medical University and H...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
National University of Medical Sciences
2024-05-01
|
| Series: | Life and Science |
| Subjects: | |
| Online Access: | https://ojs.lifenscience.org/index.php/life-and-science/article/view/632 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850199711983599616 |
|---|---|
| author | Bakhtawar Farooq Rafay-Ur-Rehman Cheema Zahid Habib Qureshi Nabeela Yasmeen Ejaz Hussain Sahu |
| author_facet | Bakhtawar Farooq Rafay-Ur-Rehman Cheema Zahid Habib Qureshi Nabeela Yasmeen Ejaz Hussain Sahu |
| author_sort | Bakhtawar Farooq |
| collection | DOAJ |
| description | Objective: This study aimed to evaluate the efficacy and safety of saroglitazar and fenofibrate in treating
diabetic dyslipidemia.
Study Design: Comparative cross-sectional study.
Place and Duration of Study: The study was conducted at the Department of Biochemistry, Nishtar Medical
University and Hospital Multan, Pakistan over 12 months from January 2021 to January 2022.
Methods: Following a 4-week run-in phase, sixty newly diagnosed patients with a previous diagnosis of
diabetes and dyslipidemia were included. Eligible participants were aged 18-65 years, with fasting triglyceride
(TG) levels >200–400 mg/dL and documented type 2 diabetes mellitus (T2DM). Following baseline
assessments, participants were randomised into two treatment groups: Saroglitazar 4 mg with 10 mg of
Atorvastatin and Fenofibrate 200 mg with 10 mg of Atorvastatin. Lipid profiles, fasting blood glucose (FBG), and
HbA1c were evaluated at baseline and after 12 weeks. Statistical analysis was conducted using appropriate
tests with p< 0.05, which is considered significant.
Results: The study enrolled 60 participants, with comparable baseline characteristics between groups. While
both treatments showed similar effects on lipid profiles, Saroglitazar showed exceptional effectiveness in
lowering HbA1c and FBG levels compared to Fenofibrate. No significant differences in adverse effects were
observed.
Conclusion: Saroglitazar may offer advantages in managing diabetic dyslipidemia and improving glycemic
control compared to Fenofibrate in a larger sample size. More investigation is necessary to confirm these
findings and evaluate long-term safety and efficacy.
How to cite this: Farooq B, Cheema RR, Qureshi ZH, Yasmeen N, Sahu EH. The Effectiveness and Safety of Fenofibrate and Saroglitazar in The Treatment of Diabetic Dyslipidemia. Life and Science. 2024; 5(2): 266-272. doi: http://doi.org/10.37185/LnS.1.1.632 |
| format | Article |
| id | doaj-art-33bca015389e4855ad28557917a8a009 |
| institution | OA Journals |
| issn | 2521-0475 2708-2970 |
| language | English |
| publishDate | 2024-05-01 |
| publisher | National University of Medical Sciences |
| record_format | Article |
| series | Life and Science |
| spelling | doaj-art-33bca015389e4855ad28557917a8a0092025-08-20T02:12:33ZengNational University of Medical SciencesLife and Science2521-04752708-29702024-05-0152070710.37185/LnS.1.1.632632The Effectiveness and Safety of Fenofibrate and Saroglitazar in the Treatment of Diabetic DyslipidemiaBakhtawar Farooq0Rafay-Ur-Rehman Cheema1Zahid Habib Qureshi2Nabeela Yasmeen3Ejaz Hussain Sahu4Nishtar Medical University, Multan, PakistanSheikh Zayed Medical College, Rahim Yar Khan, PakistanMultan Medical & Dental College, Multan, PakistanSheikh Zayed Medical College, Rahim Yar Khan, PakistanMultan Medical & Dental College, Multan, PakistanObjective: This study aimed to evaluate the efficacy and safety of saroglitazar and fenofibrate in treating diabetic dyslipidemia. Study Design: Comparative cross-sectional study. Place and Duration of Study: The study was conducted at the Department of Biochemistry, Nishtar Medical University and Hospital Multan, Pakistan over 12 months from January 2021 to January 2022. Methods: Following a 4-week run-in phase, sixty newly diagnosed patients with a previous diagnosis of diabetes and dyslipidemia were included. Eligible participants were aged 18-65 years, with fasting triglyceride (TG) levels >200–400 mg/dL and documented type 2 diabetes mellitus (T2DM). Following baseline assessments, participants were randomised into two treatment groups: Saroglitazar 4 mg with 10 mg of Atorvastatin and Fenofibrate 200 mg with 10 mg of Atorvastatin. Lipid profiles, fasting blood glucose (FBG), and HbA1c were evaluated at baseline and after 12 weeks. Statistical analysis was conducted using appropriate tests with p< 0.05, which is considered significant. Results: The study enrolled 60 participants, with comparable baseline characteristics between groups. While both treatments showed similar effects on lipid profiles, Saroglitazar showed exceptional effectiveness in lowering HbA1c and FBG levels compared to Fenofibrate. No significant differences in adverse effects were observed. Conclusion: Saroglitazar may offer advantages in managing diabetic dyslipidemia and improving glycemic control compared to Fenofibrate in a larger sample size. More investigation is necessary to confirm these findings and evaluate long-term safety and efficacy. How to cite this: Farooq B, Cheema RR, Qureshi ZH, Yasmeen N, Sahu EH. The Effectiveness and Safety of Fenofibrate and Saroglitazar in The Treatment of Diabetic Dyslipidemia. Life and Science. 2024; 5(2): 266-272. doi: http://doi.org/10.37185/LnS.1.1.632https://ojs.lifenscience.org/index.php/life-and-science/article/view/632atorvastatin, diabetes mellitus, dyslipidemias, fenofibrate, triglyceride |
| spellingShingle | Bakhtawar Farooq Rafay-Ur-Rehman Cheema Zahid Habib Qureshi Nabeela Yasmeen Ejaz Hussain Sahu The Effectiveness and Safety of Fenofibrate and Saroglitazar in the Treatment of Diabetic Dyslipidemia Life and Science atorvastatin, diabetes mellitus, dyslipidemias, fenofibrate, triglyceride |
| title | The Effectiveness and Safety of Fenofibrate and Saroglitazar in the Treatment of Diabetic Dyslipidemia |
| title_full | The Effectiveness and Safety of Fenofibrate and Saroglitazar in the Treatment of Diabetic Dyslipidemia |
| title_fullStr | The Effectiveness and Safety of Fenofibrate and Saroglitazar in the Treatment of Diabetic Dyslipidemia |
| title_full_unstemmed | The Effectiveness and Safety of Fenofibrate and Saroglitazar in the Treatment of Diabetic Dyslipidemia |
| title_short | The Effectiveness and Safety of Fenofibrate and Saroglitazar in the Treatment of Diabetic Dyslipidemia |
| title_sort | effectiveness and safety of fenofibrate and saroglitazar in the treatment of diabetic dyslipidemia |
| topic | atorvastatin, diabetes mellitus, dyslipidemias, fenofibrate, triglyceride |
| url | https://ojs.lifenscience.org/index.php/life-and-science/article/view/632 |
| work_keys_str_mv | AT bakhtawarfarooq theeffectivenessandsafetyoffenofibrateandsaroglitazarinthetreatmentofdiabeticdyslipidemia AT rafayurrehmancheema theeffectivenessandsafetyoffenofibrateandsaroglitazarinthetreatmentofdiabeticdyslipidemia AT zahidhabibqureshi theeffectivenessandsafetyoffenofibrateandsaroglitazarinthetreatmentofdiabeticdyslipidemia AT nabeelayasmeen theeffectivenessandsafetyoffenofibrateandsaroglitazarinthetreatmentofdiabeticdyslipidemia AT ejazhussainsahu theeffectivenessandsafetyoffenofibrateandsaroglitazarinthetreatmentofdiabeticdyslipidemia AT bakhtawarfarooq effectivenessandsafetyoffenofibrateandsaroglitazarinthetreatmentofdiabeticdyslipidemia AT rafayurrehmancheema effectivenessandsafetyoffenofibrateandsaroglitazarinthetreatmentofdiabeticdyslipidemia AT zahidhabibqureshi effectivenessandsafetyoffenofibrateandsaroglitazarinthetreatmentofdiabeticdyslipidemia AT nabeelayasmeen effectivenessandsafetyoffenofibrateandsaroglitazarinthetreatmentofdiabeticdyslipidemia AT ejazhussainsahu effectivenessandsafetyoffenofibrateandsaroglitazarinthetreatmentofdiabeticdyslipidemia |